Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140009/S144

Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG)

ABBOTT MEDICAL · Decision date Oct 30, 2026

MEDTECHLEDGER EXPLANATIONP140009/S144

What did the FDA decide?

FDA records this as supplement P140009/S144 to the original PMA P140009 for Abbott Medical’s Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG). The entry is a 30-Day Notice for a process change, not a new PMA approval or a statement of clinical performance.

The source names the changed item as an animal-derived to non-animal derived EBS lubricant used in TPU resin production for the BLE antenna manufacturing process. The stated scope is limited to the BLE antenna in the IPG for the bundled DBS and SCS devices; the record does not provide the technical reason for the change or any new safety or effectiveness data.

FDA approval order statement

animal-derived to non-animal derived EBS [Ethylene Bis-stearamide] lubricant to be used in TPU [thermoplastic polyurethane] resin production for the BLE [Bluetooth low energy] antenna manufacturing process. This applies specifically to the BLE antenna used in the IPG [implantable pulse generator] for either bundled device; DBS [Deep Brain Stimulator] and SCS [Spinal cord Stimulator]
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Oct 30, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P140009/S144
Regulatory pathway
PMA supplement
Product code
MHY
Decision code
OK30
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implanted, for parkinsonian tremor.

Product code
MHY
FDA device class
3

For the original device and its historical approval scope, see PMA P140009. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140009 · Original PMA

    BRIO NEUROSTIMULATION SYSTEM

  2. P140009/S140 · Related supplement

    Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger

  3. P140009/S144 received

    Application receipt date recorded by FDA.

  4. P140009/S143 · Related supplement

    Liberta RC Deep Brain Stimulation (DBS) Implantable Pulse Generator

  5. P140009/S141 · Related supplement

    Deep Brain Stimulation (DBS) EPG

  6. P140009/S142 · Related supplement

    Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger

  7. P140009/S144 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P140009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140009

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalJun 12, 2015FDA
ABBOTT MEDICALPMA supplementSep 11, 2026FDA
Infinity DBS IPGP140009/S139
ABBOTT MEDICALPMA supplementSep 23, 2026FDA
ABBOTT MEDICALPMA supplementOct 27, 2026FDA
ABBOTT MEDICALPMA supplementOct 28, 2026FDA
ABBOTT MEDICALPMA supplementOct 30, 2026FDA

Explore the linked device profile

Other records with product code MHY

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
6901 Prestion Rd., Plano, TX, 75024

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records